Diabetes Drug Market Research Report – Global Forecast to 2023
ID: MRFR/Pharma/0654-HCRR | July, 2018 | Region: Global | 80 pages | Half-Cooked Research Reports
Global Diabetes Drug Market Research Report, Type of Diabetes (Type-1 And Type-2), By Administration (Oral, Intravenous, Other), By Drug Class (Insulin, Sensitizers, SGLT-2 Inhibitors, Alpha-Glucosidase Inhibitors), By End Users (Hospital & Clinics, Ambulatory Clinics) - Forecast to 2023
Market Scenario
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two type of diabetes namely type-1 diabetes and type-2 diabetes. During last decade there is a tremendous increase in the number of diabetic population. According to International Diabetes Federation, in 2016, it was estimated that 420 million adult population were suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. A number of different types of drugs are available in the market however, no available treatment can cure diabetes totally. The global diabetic drug market is majorly driven by increasing number of diabetic population. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. To meet the increasing demand for the drugs government of different countries are providing support to manufacturers. Increasing government support will help to boost the market in coming future. However, cost issues, strict regulatory rules and long approval time for drugs may led to restrain the growth of the market.
The global diabetes drug market is expected to grow at a CAGR of 6.38% during forecasted period.
Intended Audience
- Government and Private Hospitals
- Blood banks and institutes
- Biotechnological institutes
- Pharmaceutical companies
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Medical Research Laboratories
Figure 1:- Global diabetes drug market share, by region
Sources: WHO, annual reports, press release, white paper, and company presentation
Segmentation
The global diabetes drug market is segmented on the basis of types, route of administration, drug class, and end users.
On the basis of types, the market is segmented into type-1 diabetes and type-2 diabetes.
On the basis of route of administration, the market is segmented into oral, intravenous and other.
On the basis of drug class they are insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, secretagogues, peptide analogs and others. Sensitizers are sub segmented into thiazolidinediones and biguanides. Secretagogues are further segmented into sulfonylureas and non-sulfonylureas
On the basis of end users, the market is segmented into hospital & clinics, ambulatory clinics and other.
Regional Analysis
America dominates the global diabetes drug market owing to large diabetic patient population. According to the WHO, in 2016, 9.6% of total America population were suffering from diabetes. In addition to this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. Increasing cholesterol level and smoking increases the possibility of causing diabetes. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US had diagnosed with high cholesterol level. Furthermore, increasing awareness among the people regarding different monitoring procedures, rising awareness and well-developed technology have also contributed to the growth of the market.
Europe accounts for the second largest diabetes drug market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market in Europe.
Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.
On the other hand, the Middle East & Africa has the least share in the global diabetes drug market due to presence of poor economy especially in Africa region. Middle East holds the major share in the Middle East & Africa diabetes drug market owing to well-developed healthcare sector and huge healthcare expenditure.
Research Methodology
Sources: WHO, annual reports, press release, white paper, and company presentation
Key Players for global diabetes drug market
The major player in the global diabetic drug market are Eli Lilly (US), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Biocon (US), Sunpharma (India), Sanofi (France), Novartis (Switzerland), Merck & Co. (US), Pfizer (US), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), Takeda (Japan).
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Diabetes Drug Market, by Type
6.1 Introduction
6.2 Type-1 Diabetes
Market Estimates & Forecast, 2017 – 2023
6.3 Type-2 Diabetes
Market Estimates & Forecast, 2017 – 2023
Chapter 7. Global Diabetes Drug Market, by Administration
7.1 Introduction
7.2 Oral
Market Estimates & Forecast, 2017 – 2023
7.3 Intravenous
Market Estimates & Forecast, 2017 – 2023
7.4 Others
Chapter 8 Global Diabetes Drug Market, by End User
8.1 Introduction
8.2 Insulin
Market Estimates & Forecast, 2017 – 2023
8.3 Sensitizers
Market Estimates & Forecast, 2017 – 2023
8.4 SGLT-2 Inhibitors
Market Estimates & Forecast, 2017 – 2023
8.5 Alpha-Glucosidase Inhibitors
Market Estimates & Forecast, 2017 – 2023
Chapter 9 Global Diabetes Drug Market, by End User
9.1 Introduction
9.2 Hospitals & Clinics
Market Estimates & Forecast, 2017 – 2023
9.3 Ambulatory Clinics
Market Estimates & Forecast, 2017 – 2023
9.4 Others
Market Estimates & Forecast, 2017 – 2023
Chapter 10. Global Diabetes Drug Market, by Region
10.1 Introduction
10.2 America
10.2.1 North America
10.2.1.1 US
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
Chapter 12 Company Profiles
12.1 Eli Lilly
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 AstraZeneca
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Abbott
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Biocon
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Sunpharma
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Merck & Co., Inc.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 GlaxoSmithKline plc
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Pharmaceutical industry
Chapter 14 Appendix
LIST OF TABLES
Table 1 Diabetes Drug Industry Synopsis, 2017 – 2023
Table 2 Global Diabetes Drug Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Global Diabetes Drug Market by Region, 2017 – 2023, (USD Million)
Table 4 Global Diabetes Drug Market by Types, 2017 – 2023, (USD Million)
Table 5 Global Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)
Table 6 Global Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)
Table 7 Global Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)
Table 8 North America Diabetes Drug Market by Types, 2017 – 2023, (USD Million)
Table 9 North America Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)
Table 10 North America Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)
Table 11 North America Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)
Table 12 US Market by Types, 2017 – 2023, (USD Million)
Table 13 US Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)
Table 14 US Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)
Table 15 US Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)
Table 16 Canada Market by Types, 2017 – 2023, (USD Million)
Table 17 Canada Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)
Table 18 Canada Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)
Table 19 Canada Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)
Table 20 South America Market by Types, 2017 – 2023, (USD Million)
Table 21 South America Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)
Table 22 South America Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)
Table 23 South America Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)
Table 24 Europe Market by Types, 2017 – 2023, (USD Million)
Table 25 Europe Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)
Table 26 Europe Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)
Table 27 Europe Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)
Table 28 Western Europe Market by Types, 2017 – 2023, (USD Million)
Table 29 Western Europe Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)
Table 30 Western Europe Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)
Table 31 Eastern Europe Market by Types, 2017 – 2023, (USD Million)
Table 32 Eastern Europe Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)
Table 33 Eastern Europe Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)
Table 34 Eastern Europe Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)
Table 35 Asia Pacific Market by Types, 2017 – 2023, (USD Million)
Table 36 Asia Pacific Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)
Table 37 Asia Pacific Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)
Table 38 Asia Pacific Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)
Table 39 Middle East & Africa Market by Types, 2017 – 2023, (USD Million)
Table 40 Middle East & Africa Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)
Table 41 The Middle East & Africa Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)
Table 42 Middle East & Africa Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Diabetes Drug Market
Figure 3 Segmentation Market Dynamics for Global Diabetes Drug Market
Figure 4 Global Diabetes Drug market Share, by Type 2016
Figure 5 Global Diabetes Drug market Share, by Administration 2016
Figure 6 Global Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)
Figure 7 Global Diabetes Drug Market Share, by End Users, 2016
Figure 8 Global Diabetes Drug Market Share, by Region, 2016
Figure 9 North America Diabetes Drug Market Share, by Country, 2016
Figure 10 Europe Diabetes Drug Market Share, by Country, 2016
Figure 11 Asia Pacific Diabetes Drug Market Share, by Country, 2016
Figure 12 Middle East & Africa Diabetes Drug Market Share, by Country, 2016
Figure 13 Global Diabetes Drug Market: Company Share Analysis, 2016 (%)
Figure 14 Eli Lilly: Key Financials
Figure 15 Eli Lilly: Segmental Revenue
Figure 16 Eli Lilly: Geographical Revenue
Figure 17 AstraZeneca: Key Financials
Figure 18 AstraZeneca: Segmental Revenue
Figure 19 AstraZeneca: Geographical Revenue
Figure 20 Abbott: Key Financials
Figure 21 Abbott: Segmental Revenue
Figure 22 Abbott: Geographical Revenue
Figure 23 Sunpharma: Key Financials
Figure 24 Sunpharma: Segmental Revenue
Figure 25 Sunpharma: Geographical Revenue
Figure 26 Merck & Co., Inc.: Key Financials
Figure 27 Merck & Co., Inc.: Segmental Revenue
Figure 28 Merck & Co., Inc.: Geographical Revenue
Figure 29 GlaxoSmithKline plc: Key Financials
Figure 30 GlaxoSmithKline plc: Segmental Revenue
Figure 31 GlaxoSmithKline plc: Geographical Revenue
Figure 32 Sanofi: Key Financials
Figure 33 Sanofi: Segmental Revenue
Figure 34 Sanofi: Geographical Revenue
